Ginkgo biloba extract EGb 761® in the treatment of dementia: A pharmacoeconomic analysis of the Austrian setting

Wiener Klinische Wochenschrift

Volumn 125, Issue 1-2, 2013, Pages 8-15

  Rainer, Michael ^a   Mucke, Hermann ^b   Schlaefke, Sandra ^c  

^a Department of Psychiatry   (Austria)

^b HM Pharma Consultancy   (Austria)

^c DR WILLMAR SCHWABE GMBH AND CO KG   (Germany)

Author keywords

Austria; Dementia; Economics; EGb 761 ; Ginkgo biloba; Pharmaceutical

Indexed keywords

GINKGO BILOBA EXTRACT; PLACEBO;

ARTICLE; AUSTRIA; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMENTIA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG COST; HUMAN; MAJOR CLINICAL STUDY; MEDICAL FEE; REIMBURSEMENT; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AUSTRIA; DEMENTIA; ECONOMICS, PHARMACEUTICAL; FEES, MEDICAL; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PLANT EXTRACTS; PREVALENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 84873434547     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-012-0307-x     Document Type: Article

References (23)

1. Kleijnen J, Knipschild P. Ginkgo biloba for cerebral insufficiency. Br J Clin Pharmacol. 1992;34(4):352-8.
2. Hörr R, Kieser M. Pharmaco-economic evaluation of Ginkgo special extract EGb 761® for dementias in Austria. Wien Med Wochenschr. 2002;152(15-16):427-31 (in German).
3. Haan J, Hörr R. Delay in progression of dependency and need of care of dementia patients treated with Ginkgo special extract EGb 761®. Wien Med Wochenschr. 2004;154(21-22):511-4 (in German).
4. Napryeyenko O, Borzenko I, GINDEM-NP Study Group. Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneimittelforschung. 2007;57(1):4-11.
5. Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, et al. on behalf of the GOTADAY Study Group. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry. 2011;26(11):1186-94.
6. Herrschaft H, Nacu A, Likhachev S, Sholomov I, Hoerr R, Schlaefke S. Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: a randomized, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res. 2012;46(3):713-23.
7. Institute for Quality and Efficiency in Health Care (IQWiG). Ginkgo in Alzheimer's disease. Executive summary. IQWiG reports - Commission no. A05-19B. Version 1.0; Status: 29.09.2008.
8. Bracco L, Gallato R, Grigoletto F, et al. Factors affecting course and survival in Alzheimer's disease. A 9-year longitudinal study. Arch Neurol. 1994;51(12):1213-9.
9. Heyman A, Peterson B, Fillenbaum G, Pieper C. The consortium to establish a registry for Alzheimer's disease (CERAD). Part XIV: Demographic and clinical predictors of survival in patients with Alzheimer's disease. Neurology. 1996;46(3):656-60
10. Statistik Austria. Gesundheitsbefragung 2006/07. Compiled July 18, 2008. http://www.statistik.at/web-de/static/ambulante-versorgung-200607-022268.pdf. WebCite Archive URL: http://www.webcitation.org/66Niy7Nu2. Accessed 18 Dec 2012.
11. Versicherungsanstalt für Eisenbahnen und Bergbau. Information über das Bundespflegegeld (Stand: 1. Jänner 2012). https://www.sozialversicherung.at/mediaDB/633780- Infoblatt%20Bundespflegegeld%20%20Stand%201.1.2010.pdf%20- %20Adobe%20Acrobat%20Professional.pdf. WebCite Archive URL: http://www. webcitation.org/66NiPxD1l. Accessed 18 Dec 2012.
12. Mega MS, Masterman DM, O'Connor SM, et al. The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease. Arch Neurol. 1999;56(11):1388-93.
13. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl. 2):S22-32.
14. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD005593. doi: 10.1002/14651858.CD005593.
15. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH, on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. Section 12.5.4.3. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.1.0, updated March 2011. The Cochrane Collaboration. 2011. www.cochrane-handbook.org/. Accessed 1 Aug 2011.
16. Cates CJ. Simpson's paradox and calculation of number needed to treat from metaanalysis. BMC Med Res Methodol. 2002;2:1.
17. Österreichischer Apotheker-Verlag Warenverzeichnis I des Österreichischen Apotheker-Verlages. Wien: Österreichische Apotheker-Verlagsgesellschaft mbH, Mai 2012. http://warenverzeichnis.apoverlag. at. Accessed 31 May 2012.
18. Scripnikov A, Khomenko A, Napryeyenko O, GINDEM-NP Study Group. Effects of Ginkgo biloba extract EGb 761® on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial. Wien Med Wochenschr. 2007;157(13-14):295-300.
19. Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®. Findings from a randomized controlled trial. Neuropsychiatr Dis Treat. 2011;7:209-15.
20. Nacu A, Hörr R, Herrschaft H. Neuropsychiatric symptoms of dementia and related caregiver distress: effect of treatment by a once-daily formulation of Ginkgo biloba extract EGb 761®. Alzheimer's & Dementia. 2011;7(4 Suppl. 1):S785.
21. Gilley DW, Bienias JL, Wilson RS, et al. Influence of behavioral symptoms on rates of institutionalization for persons with Alzheimer's disease. Psychol Med. 2004;34(6):1129-35.
22. de Vugt ME, Stevens F, Aalten P, et al. A prospective study of the effects of behavioral symptoms on the institutionalization of patients with dementia. Int Psychogeriatr. 2005;17(4):577-89.
23. Committee for Medicinal Products for Human Use (CHMP). Guideline on medicinal products for the treatment of Alzheimer's disease and other dementias. Doc. Ref. CPMP/EWP/553/95 Rev. 1. London, 24 July 2008. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003562.pdf. Accessed 18 Dec 2012.